CSF2 and melanoma: Intratumoral administration of talimogene laherparepvec (T-VEC), a genetically modified herpes simplex virus type 1 encoding granulocyte macrophage colony-stimulating factor (GM-CSF), has proved its clinical benefit for patients with advanced melanoma [6–9].